12 recruiting, 8 active not recruiting, 4 completed, 3 unknown. 31 Phase 2, 9 Phase 1.
Follow Melanoma Stage IV: new trials by email Literature Review of Melanoma Stage IV trials Research Report on Melanoma Stage IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma Opdualag, Nivolumab - Cutaneous Melanoma, Melanoma Stage IV | Phase 2 | Recruiting | University Health Network, Toronto | 54 | 2026-11-30 | 2026-10-13 |
| Screening for Brain Metastases gadopiclenol (contrast agent), standard contrast agent - Lung Cancer Stage IV, Melanoma Stage IV | Phase 2 | Not yet recruiting | University of Zurich | 180 | 2026-09-01 | 2026-03-25 |
| NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma Pembrolizumab, Ipilimumab plus nivolumab - Melanoma (Skin Cancer), Melanoma Stage Stage IIIB | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 55 | 2026-08-06 | 2026-09-30 |
| Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma Pembrolizumab, Cyclophosphamide - Melanoma, Melanoma Stage III | Phase 2 | Recruiting | University of California, Irvine | 14 | 2024-12-23 | 2026-03-10 |
| Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients L19IL2, L19TNF, L19IL2/L19TNF - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | Philogen S.p.A. | 162 | 2024-07-12 | 2026-09-02 |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2024-05-17 | 2026-04-01 |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors GIM-531, Anti-PD-1 monoclonal antibody - Melanoma Stage IV, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Georgiamune Inc | 117 | 2024-05-09 | 2026-08-14 |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) - Cancer, Melanoma Stage III | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 240 | 2023-10-31 | 2025-05-18 |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma [203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-06-01 | 2026-10-13 |
| A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma Regorafenib 40 MG Oral Tablet, Triplet therapy - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | Universitair Ziekenhuis Brussel | 48 | 2022-10-03 | 2026-09-30 |
| A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma EVX-01, Pembrolizumab 25 MG/ML - Melanoma Stage IV, Unresectable Melanoma | Phase 2 | Active not recruiting | Evaxion Biotech A/S | 17 | 2022-09-19 | 2025-09-22 |
| FMT to Convert Response to Immunotherapy Fecal microbiota transplantation - Melanoma Stage III, Melanoma Stage IV | Phase 1 / Phase 2 | Recruiting | The Netherlands Cancer Institute | 24 | 2022-08-31 | 2025-03-10 |
| Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders Fecal Microbiota Transplant (FMT) - Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Oslo University Hospital | 20 | 2022-06-28 | 2025-07-03 |
| Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT - Sarcoma, Synovial, Sarcoma,Soft Tissue | Phase 1 / Phase 2 | Recruiting | Hadassah Medical Organization | 3 | 2022-04-01 | 2025-10-02 |
| A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment BNT111, Cemiplimab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Completed | BioNTech SE | 184 | 2021-05-19 | 2026-01-08 |
| Surgery of Melanoma Metastases After Systemic Therapy Surgical metastasectomy, Immunotherapy - Melanoma, Melanoma Stage IV | Phase 2 | Withdrawn | Vastra Gotaland Region | 2021-03-11 | 2024-01-26 | |
| Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma Binimetinib, Imatinib - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | University of California, San Francisco | 25 | 2021-03-03 | 2026-08-18 |
| A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC Fecal Microbial Transplantation by capsules - Melanoma Stage IV, Unresectable Melanoma | Phase 1 / Phase 2 | Unknown | Ella Therapeutics Ltd | 42 | 2020-11-01 | 2021-08-16 |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients Interleukin-2, Ipilimumab, Nivolumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 18 | 2020-09-24 | 2026-09-02 |
| Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease T-VEC - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Completed | The Netherlands Cancer Institute | 24 | 2020-09-08 | 2025-03-12 |
Showing 20 of 31. Sign in to see all of them.
Melanoma (31) · Carcinoma, Non-Small-Cell Lung (3) · Brain Neoplasms (2) · Skin Neoplasms (2) · Adenoviridae Infections (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Colitis (1) · Drug-Related Side Effects and Adverse Reactions (1) · Glioblastoma (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neuroblastoma (1) · Ovarian Neoplasms (1)
Neoplasms by Histologic Type (31) · Neoplasms by Site (31) · Neoplasms, Germ Cell and Embryonal (31) · Neoplasms, Nerve Tissue (31) · Neuroectodermal Tumors (31) · Neuroendocrine Tumors (31) · Nevi and Melanomas (31) · Skin Diseases (31) · Skin and Connective Tissue Diseases (31) · Neoplasms (30) · Skin Neoplasms (29) · Lung Diseases (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4) · Thoracic Neoplasms (4)
Nivolumab (11) · Ipilimumab (7) · pembrolizumab (5) · Opdualag (3) · Cyclophosphamide (2) · Denosumab (2) · Fecal Microbiota Transplantation (2) · Interleukin-2 (2) · aldesleukin (2) · Contrast Media (1) · Imatinib Mesylate (1) · Immunotherapy (1) · Infliximab (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1)
Evaxion Biotech A/S (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · The Netherlands Cancer Institute (2) · UNC Lineberger Comprehensive Cancer Center (2) · BioNTech SE (1) · Dana-Farber Cancer Institute (1) · Diwakar Davar (1) · Ella Therapeutics Ltd (1) · Georgiamune Inc (1) · Hadassah Medical Organization (1) · Krystal Biotech, Inc. (1) · Massachusetts General Hospital (1) · Melanoma Institute Australia (1) · Melanoma and Skin Cancer Trials Limited (1) · Oslo University Hospital (1)
United States (16) · Australia (5) · Italy (3) · United Kingdom (3) · Germany (2) · Israel (2) · Netherlands (2) · Norway (2) · Belgium (1) · Canada (1) · Japan (1) · Poland (1) · Spain (1) · Sweden (1) · Switzerland (1)
Ahmad Tarhini, MD, PhD (2) · Stergios Moschos, MD (2) · Abi Vainstein-Haras, MD (1) · Danielle Bello (1) · David Chien, MD (1) · Diwakar Davar, MD (1) · Dr Bavanthi Balakrishnar (1) · Elizabeth I Buchbinder, MD (1) · Georgina V Long, MBBS PhD (1) · Guy Ben-Betzalel, MD (1) · John Haanen, Prof (1) · John Haanen, Prof. (1) · Jon Amund Kyte, MD, Ph.D. (1)
PMID 31917762, PMID 33450821, PMID 35927710, PMID 36047545, PMID 36585700, PMID 36648215, PMID 42476727
2023 (1)